NCT02997982View on ClinicalTrials.gov

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
Alzheimer DiseaseMild Cognitive ImpairmentHerpes Simplex
Interventions
DRUG

Valaciclovir 500Mg Tablet

Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.

Trial Locations (2)

90185

Geriatric Centre, University Hospital in Umeå, Umeå

Unknown

Memory Clinic, Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Hugo Lovheim

OTHER

NCT02997982 - Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter